According to the Department of Health and Human Services’ semiannual agenda, the U.S. Food and Drug Administration (FDA) plans to issue a final rule that would allow generic drug makers to follow the same process as branded drug manufacturers in updating safety information on product labeling. Proposed on November 13, 2013, the rule would “enable ANDA [abbreviated new drug application] holders to update product labeling promptly to reflect certain types of newly acquired information related to drug safety, irrespective of whether the revised labeling differs from that of the RLD [reference listed drug].” See Federal Register, June 13, 2014.